Skip to main
PHGE
PHGE logo

BiomX Inc. (PHGE) Stock Forecast & Price Target

BiomX Inc. (PHGE) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BiomX Inc. is positioned positively due to its innovative phage-based technology aimed at addressing unmet medical needs in chronic diseases, such as cystic fibrosis and diabetic foot osteomyelitis. The company’s strategic trial design for the BX211 product candidate, which could significantly improve disease severity, creates a favorable outlook for its phage therapies. Furthermore, potential for increased market penetration, expansion into additional indications, and growth in international markets underpins an optimistic valuation trajectory for BiomX.

Bears say

BiomX Inc. faces significant headwinds in achieving commercial success for its therapeutic phage products due to potential failed or inconclusive clinical trials that could jeopardize ongoing development efforts. The financial outlook is further complicated by the company’s challenges in securing adequate funding, which may hinder the advancement of their drug candidates through the necessary development pathways. Additionally, the risk of dilutive capital raises may negatively impact shareholder value, contributing to a negative sentiment surrounding the stock.

BiomX Inc. (PHGE) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BiomX Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BiomX Inc. (PHGE) Forecast

Analysts have given BiomX Inc. (PHGE) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BiomX Inc. (PHGE) has a Strong Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BiomX Inc. (PHGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.